歌礼制药-B(01672.HK):向美国FDA递交ASC30_39 FDC治疗肥胖症的新药临床试验申请,其有望成为同类首创口服小分子GLP-1R激动剂与选择性胰淀素受体激动剂的固定剂量复方制剂

智通财经
Nov 11
【歌礼制药-B(01672.HK):向美国FDA递交ASC30_39 FDC治疗肥胖症的新药临床试验申请,其有望成为同类首创口服小分子GLP-1R激动剂与选择性胰淀素受体激动剂的固定剂量复方制剂】智通财经APP讯,歌礼制药-B(01672.HK)发布公告,公司已向美国食品药品监督管理局(FDA)递交ASC30_39 FDC用于肥胖症治疗的新药临床试验申请(IND)。 ASC30_39 FDC是小分子GLP-1R激动剂ASC30与小分子选择性胰淀素受体激动剂 (SARA)ASC39的每日一次口服固定剂量复方制剂(FDC)片。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10